A New MicroRNA Expression Signature for Cervical Cancer

2017 ◽  
Vol 27 (2) ◽  
pp. 339-343 ◽  
Author(s):  
Ping Sun ◽  
Yong Shen ◽  
Jiao-Mei Gong ◽  
Li-Li Zhou ◽  
Jia-He Sheng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Intraepithelial Neoplasia ◽  
Lymph Node Involvement ◽  
Healthy Controls ◽  
Aberrant Expression ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Node Involvement ◽  
Novel Biomarkers ◽  
Cancer Tissues

BackgroundCervical cancer is the second most common cancer among women worldwide. The potential of microRNAs as novel biomarkers in cervical cancer is growing.ObjectivesIn this study, we investigated the functions and targets of miR-466 in cervical cancer tissues.MethodsFresh cervical tissues were obtained from 157 patients with cervical cancer, cervical intraepithelial neoplasia (CIN), and healthy controls, and the tissues were immediately frozen in liquid nitrogen until use. The RNA was extracted and quantitative real-time polymerase chain reaction (PCR) was performed.ResultsA total of 157 participants were summarized, including 56 patients with cervical cancer, 60 patients with CIN, and 49 healthy controls. The expression levels of miR-466 in cervical cancers (0.68) were higher than that in healthy controls (0.082) (P < 0.01). The average fold changes of miR-466 in the patients with CIN group and people group were 0.28 and 0.082, respectively (P < 0.01). It was a statistically significant difference in patients with lymph node involvement (P = 0.022). However, the expression of miR-466 was not correlated with International Federation of Gynecology and Obstetrics stages, tumor size, or vascular invasion (P = 0.506, P = 0.667, and P = 0.108, respectively).ConclusionsOur results indicate that the aberrant expression of miR-466 is closely associated with the occurrence and development of cervical cancer.

scholarly journals Nm23 expression in endometrial and cervical cancer: inverse correlation with lymph node involvement and myometrial invasion

1996 ◽  
Vol 74 (7) ◽  
pp. 1063-1068 ◽  
Author(s):  
M Marone ◽  
G Scambia ◽  
G Ferrandina ◽  
C Giannitelli ◽  
P Benedetti-Panici ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Myometrial Invasion ◽  
Inverse Correlation ◽  
Lymph Node Involvement ◽  
Node Involvement

MiR-195 Suppresses Cervical Cancer Migration and Invasion Through Targeting Smad3

2016 ◽  
Vol 26 (5) ◽  
pp. 817-824 ◽  
Author(s):  
Quan Zhou ◽  
Ling R. Han ◽  
Yang X. Zhou ◽  
Yan Li
Keyword(s):  
Cervical Cancer ◽  
Cell Lines ◽  
Cancer Metastasis ◽  
Luciferase Reporter ◽  
Migration And Invasion ◽  
Gynecology And Obstetrics ◽  
Clinicopathological Significance ◽  
Cervical Cancer Development ◽  
Cancer Tissues

ObjectiveMicroRNAs (miRNAs) play crucial roles in cervical cancer development and progression. The purposes of this study were to investigate the role of miR-195 in cervical cancer and clarify the regulation of Smad3 by miR-195.MethodsQuantitative real-time polymerase chain reaction was used to examine miR-195 expression in cervical cancer tissues and cell lines. The clinicopathological significance of miR-195 down-regulation was further analyzed. Transwell migration and invasion assays were performed. A luciferase reporter assay was conducted to confirm the target gene of miR-195, and the results were validated in cervical cancer tissues and cell lines.ResultsMiR-195 was significantly decreased in clinical tissues and cervical cancer cell lines. The low miR-195 level was significantly correlated with higher International Federation of Gynecology and Obstetrics stage, node metastasis, and deep stromal invasion. Up-regulation of miR-195 suppressed cell migration and invasion in vitro. Smad3 was verified as a direct target of miR-195, which was further confirmed by the inverse expression of miR-195 and Smad3 in patients’ specimens.ConclusionsThe newly identified miR-195/Smad3 pathway provides an insight into cervical cancer metastasis and may represent a novel therapeutic target.

Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

2002 ◽  
Vol 20 (4) ◽  
pp. 966-972 ◽  
Author(s):  
R. Pearcey ◽  
M. Brundage ◽  
P. Drouin ◽  
J. Jeffrey ◽  
D. Johnston ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Lymph Node Involvement ◽  
Phase Iii ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Cancer Of The Cervix

PURPOSE: To test the hypothesis that cisplatin (CDDP) administered concurrently with standard radiotherapy (RT) would improve pelvic control and survival in patients with advanced squamous cell cancer of the cervix. PATIENTS AND METHODS: A total of 259 patients with International Federation of Gynecology and Obstetrics stage IB to IVA squamous cell cervical cancer with central disease ≥ 5 cm or histologically confirmed pelvic lymph node involvement were randomized to receive RT (external-beam RT plus brachytherapy) plus weekly CDDP chemotherapy (40 mg/m2) (arm 1) or the same RT without chemotherapy (arm 2). RESULTS: A total of 253 patients were available for analysis. Median follow-up was 82 months. No significant difference was found in progression-free survival (P = .33). No significant difference in 3- and 5-year survival rates was found (69% v 66% and 62% v 58%, respectively; P = .42). The hazard ratio for survival (arm 2 to arm 1) was 1.10 (95% confidence interval, 0.75 to 1.62). CONCLUSION: This study did not show a benefit to either pelvic control or survival by adding concurrent weekly CDDP chemotherapy in a dose of 40 mg/m2 to radical RT as given in this trial. Careful attention to RT details is important for achieving optimum outcome for patients with this disease.

scholarly journals Human papillomavirus and human telomerase RNA component gene in cervical cancer progression

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Yang Liu ◽  
Pianping Fan ◽  
Yingying Yang ◽  
Changjun Xu ◽  
Yajuan Huang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Progression ◽  
Invasive Cervical Cancer ◽  
Intraepithelial Neoplasia ◽  
Hpv Infection ◽  
Cancer Group ◽  
Potential Marker ◽  
Significant Difference ◽  
Human Telomerase

Abstract This study aimed to examine hTERC gene in different grades of cervical intraepithelial neoplasia (CIN) and cervical cancer, and the association between hTERC and high risk-human papillomavirus (HR-HPV) infection. Patients who underwent cervical cancer screening at the Second Affiliated Hospital of Kunming Medical University between October 2010 and December 2011 were enrolled. All patients underwent liquid-based cytology test and hybrid capture 2 (HC2) for HPV detection. hTERC was examined using fluorescence in situ hybridization (FISH). Cervical colposcopy biopsy was performed if any of the three results was positive. HC2, FISH, and pathology were compared. A total of 1200 women underwent screening, 150 patients underwent cervical biopsy: 32 in the normal group, 38 in the CIN1 group, 66 in the CIN2/3 group, and 14 in the invasive cervical cancer group. More patients had HR-HPV infection in the CIN2/3 group and ICC group compared with the CIN1 group. hTERC increased with increasing histological dysplasia. There was significant difference in hTERC positive rate between each of the three groups. More patients with hTERC gene amplification were observed in the positive HR-HPV group than in the HR-HPV negative group. In conclusion, hTERC is a potential marker for precancerous cervical cancer lesions. hTERC might be correlated with HR-HPV infection in cervical diseases.

scholarly journals Does lymph node involvement affect the patterns of recurrence in stage IB cervical cancer?

2014 ◽  
Vol 44 ◽  
pp. 844-852 ◽  
Author(s):  
Işın ÜREYEN ◽  
Ülkü AKSOY ◽  
Betül DÜNDAR ◽  
Ömer Lütfi TAPISIZ ◽  
Mustafa Alper KARALÖK ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Lymph Node Involvement ◽  
Stage Ib ◽  
Node Involvement ◽  
Patterns Of Recurrence

Effect of Treatment Delay on Survival in Patients With Cervical Cancer: A Historical Cohort Study

2014 ◽  
Vol 24 (7) ◽  
pp. 1326-1332 ◽  
Author(s):  
Tamar Perri ◽  
Gal Issakov ◽  
Gilad Ben-Baruch ◽  
Shira Felder ◽  
Mario E. Beiner ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cohort Study ◽  
Waiting Time ◽  
Treatment Initiation ◽  
Treatment Delay ◽  
Lymph Node Involvement ◽  
Continuous Variable ◽  
Node Involvement ◽  
Group 3 ◽  
Effect Of Treatment

ObjectiveThe objective of this study was to evaluate the effect of treatment delay on prognosis in patients with cervical cancer.MethodsThe study group of this historic cohort study comprised 321 patients newly diagnosed with cervical cancer between 1999 and 2010. Time from diagnosis to treatment was analyzed both as a continuous variable and as a categorical variable in 3 groups that differed in waiting time between diagnosis and treatment initiation: 30 days or less (group 1, n = 134), 30 to 45 days (group 2, n = 86), and more than 45 days (group 3, n = 101). Associations between waiting time group, patients’ characteristics, and disease outcome were investigated usingttests, analyses of variance and Cox regression analyses, Kaplan-Meier survival analysis, and log-rank (Mantel-Cox) tests.ResultsTime from diagnosis to treatment initiation, when analyzed as a continuous variable, was not a significant factor in survival. There were no between-group differences in age, smoking rate, marital status, gravidity, parity, tumor histology, or lymph node involvement. Early-stage disease and small tumor diameter were diagnosed most frequently in group 3. However, there was no significant between-group difference in 3-year survival rates (74.6%, 82.2%, and 80.8% in groups 1, 2, and 3, respectively;P= 0.38). On multivariate analysis, only stage, histology, and lymph node involvement were significant prognostic factors for survival. Before starting treatment, 28 patients underwent ovarian preservation procedures.ConclusionsLonger waiting time from diagnosis to treatment was not associated with worse survival. Our findings imply that if patients desire fertility or ovarian preservation procedures before starting treatment, it is acceptable to allow time for them.

scholarly journals Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients with Colorectal Cancer

Proteomes ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 26
Author(s):  
Juthamard Chantaraamporn ◽  
Voraratt Champattanachai ◽  
Amnart Khongmanee ◽  
Chris Verathamjamras ◽  
Naiyarat Prasongsook ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Interaction Analysis ◽  
Study Cohort ◽  
Healthy Controls ◽  
Label Free ◽  
Aberrant Expression ◽  
Protein Protein Interaction ◽  
Acetylneuraminic Acid ◽  
Novel Biomarkers ◽  
Complement C9

Colorectal cancer (CRC) is a major cause of cancer mortality. Currently used CRC biomarkers provide insufficient sensitivity and specificity; therefore, novel biomarkers are needed to improve the CRC detection. Label-free quantitative proteomics were used to identify and compare glycoproteins, enriched by wheat germ agglutinin, from plasma of CRC patients and age-matched healthy controls. Among 189 identified glycoproteins, the levels of 7 and 15 glycoproteins were significantly altered in the non-metastatic and metastatic CRC groups, respectively. Protein-protein interaction analysis revealed that they were predominantly involved in immune responses, complement pathways, wound healing and coagulation. Of these, the levels of complement C9 (C9) was increased and fibronectin (FN1) was decreased in both CRC states in comparison to those of the healthy controls. Moreover, their levels detected by immunoblotting were validated in another independent cohort and the results were consistent with in the study cohort. Combination of CEA, a commercial CRC biomarker, with C9 and FN1 showed better diagnostic performance. Interestingly, predominant glycoforms associated with acetylneuraminic acid were obviously detected in alpha-2 macroglobulin, haptoglobin, alpha-1-acid glycoprotein 1, and complement C4-A of CRC patient groups. This glycoproteomic approach provides invaluable information of plasma proteome profiles of CRC patients and identification of CRC biomarker candidates.

Sign in / Sign up

Export Citation Format

Share Document